Table 4

Multivariate analysis

OutcomeNo.Relative risk (95% CI)P
Treatment-related mortality    
    Age at HCT    
        35 y or younger 339 1.00  
        Older than 35 y 518 1.38 (1.11-1.70) .003 
    Karnofsky Lansky score prior to HCT    
        90% or higher 523 1.00 Poverall = .002 
        Lower than 90% 290 1.44 (1.17-1.78) .001 
        Unknown 44 0.88 (0.54-1.43) .61 
    Disease status prior to HCT    
        t-AML, CR1 277 1.00 Poverall = .007 
        t-AML, CR2 or beyond 38 0.97 (0.58-1.63) .92 
        t-AML, not in CR 226 1.27 (0.96-1.68) .09 
        t-MDS, early 110 1.69 (1.23-2.34) .001 
        t-MDS, advanced 206 1.47 (1.13-1.93) .005 
    Type of donor    
        HLA-identical sibling 277 1.00 Poverall < .001 
        Other relative 46 2.77 (1.84-4.17) < .001 
        URD, well matched 204 0.81 (0.60-1.10) .17 
        URD, partially matched 224 1.19 (0.92-1.56) .19 
        URD, mismatched 106 1.78 (1.31-2.43) < .001 
Relapse    
    Age at HCT    
        35 y or younger 339 1.00  
        Older than 35 y 518 1.56 (1.17-2.09) .003 
    Prior disease    
        Lymphoma; plasma cell disorders; CLL 395 1.00 Poverall = .006 
        Acute lymphoblastic leukemia 100 1.82 (1.23-2.71) .003 
        Other malignancies 317 1.01 (0.76-1.33) .95 
        Nonmalignancies or others 45 0.66 (0.35-1.24) .19 
    Cytogenetics    
        No abnormalities/ intermediate prognosis 436 1.00 Poverall = .001 
        Good/favorable prognosis 66 0.55 (0.22-1.35) .19 
        Poor/unfavorable prognosis 248 1.72 (1.28-2.29) < .001 
        Unknown 140 1.32 (0.93-1.88) .12 
    Disease status prior to HCT    
        t-AML, CR1 277 1.00 Poverall < .001 
        t-AML, CR2 or beyond 38 1.19 (0.59-2.42) .63 
        t-AML, not in CR 226 3.36 (2.44-4.64) < .001 
        t-MDS, early 110 1.07 (0.66-1.75) .77 
        t-MDS, advanced 206 1.55 (1.07-2.25) .02 
Overall survival    
    Age at HCT    
        35 y or younger 340 1.00  
        Older than 35 y 528 1.34 (1.14-1.59) .001 
    Cytogenetics    
        No abnormalities/intermediate prognosis 443 1.00 Poverall = .002 
        Good/favorable prognosis 33 0.82 (0.52-1.30) .40 
        Poor/unfavorable prognosis 251 1.41 (1.17-1.70) < .001 
        Unknown 141 1.22 (0.98-1.52) .07 
    Disease status prior to HCT    
        t-AML, CR1 279 1.00 Poverall < .001 
        t-AML, CR2 or beyond 38 1.07 (0.70-1.63) .77 
        t-AML, not in CR 228 1.95 (1.59-2.39) < .001 
        t-MDS, early 111 1.34 (1.02-1.77) .035 
        t-MDS, advanced 212 1.44 (1.15-1.79) .001 
    Type of donor    
        HLA-identical sibling 282 1.00 Poverall < .001 
        Other relative 47 2.06 (1.48-2.86) < .001 
        URD, well matched 204 0.92 (0.73-1.14) .44 
        URD, partially matched 227 1.10 (0.89-1.35) .38 
        URD, mismatched 108 1.51 (1.18-1.93) .001 
OutcomeNo.Relative risk (95% CI)P
Treatment-related mortality    
    Age at HCT    
        35 y or younger 339 1.00  
        Older than 35 y 518 1.38 (1.11-1.70) .003 
    Karnofsky Lansky score prior to HCT    
        90% or higher 523 1.00 Poverall = .002 
        Lower than 90% 290 1.44 (1.17-1.78) .001 
        Unknown 44 0.88 (0.54-1.43) .61 
    Disease status prior to HCT    
        t-AML, CR1 277 1.00 Poverall = .007 
        t-AML, CR2 or beyond 38 0.97 (0.58-1.63) .92 
        t-AML, not in CR 226 1.27 (0.96-1.68) .09 
        t-MDS, early 110 1.69 (1.23-2.34) .001 
        t-MDS, advanced 206 1.47 (1.13-1.93) .005 
    Type of donor    
        HLA-identical sibling 277 1.00 Poverall < .001 
        Other relative 46 2.77 (1.84-4.17) < .001 
        URD, well matched 204 0.81 (0.60-1.10) .17 
        URD, partially matched 224 1.19 (0.92-1.56) .19 
        URD, mismatched 106 1.78 (1.31-2.43) < .001 
Relapse    
    Age at HCT    
        35 y or younger 339 1.00  
        Older than 35 y 518 1.56 (1.17-2.09) .003 
    Prior disease    
        Lymphoma; plasma cell disorders; CLL 395 1.00 Poverall = .006 
        Acute lymphoblastic leukemia 100 1.82 (1.23-2.71) .003 
        Other malignancies 317 1.01 (0.76-1.33) .95 
        Nonmalignancies or others 45 0.66 (0.35-1.24) .19 
    Cytogenetics    
        No abnormalities/ intermediate prognosis 436 1.00 Poverall = .001 
        Good/favorable prognosis 66 0.55 (0.22-1.35) .19 
        Poor/unfavorable prognosis 248 1.72 (1.28-2.29) < .001 
        Unknown 140 1.32 (0.93-1.88) .12 
    Disease status prior to HCT    
        t-AML, CR1 277 1.00 Poverall < .001 
        t-AML, CR2 or beyond 38 1.19 (0.59-2.42) .63 
        t-AML, not in CR 226 3.36 (2.44-4.64) < .001 
        t-MDS, early 110 1.07 (0.66-1.75) .77 
        t-MDS, advanced 206 1.55 (1.07-2.25) .02 
Overall survival    
    Age at HCT    
        35 y or younger 340 1.00  
        Older than 35 y 528 1.34 (1.14-1.59) .001 
    Cytogenetics    
        No abnormalities/intermediate prognosis 443 1.00 Poverall = .002 
        Good/favorable prognosis 33 0.82 (0.52-1.30) .40 
        Poor/unfavorable prognosis 251 1.41 (1.17-1.70) < .001 
        Unknown 141 1.22 (0.98-1.52) .07 
    Disease status prior to HCT    
        t-AML, CR1 279 1.00 Poverall < .001 
        t-AML, CR2 or beyond 38 1.07 (0.70-1.63) .77 
        t-AML, not in CR 228 1.95 (1.59-2.39) < .001 
        t-MDS, early 111 1.34 (1.02-1.77) .035 
        t-MDS, advanced 212 1.44 (1.15-1.79) .001 
    Type of donor    
        HLA-identical sibling 282 1.00 Poverall < .001 
        Other relative 47 2.06 (1.48-2.86) < .001 
        URD, well matched 204 0.92 (0.73-1.14) .44 
        URD, partially matched 227 1.10 (0.89-1.35) .38 
        URD, mismatched 108 1.51 (1.18-1.93) .001 

CI indicates confidence interval; HCT indicates hematopoietic cell transplantation; t-AML, therapy-related acute myeloid leukemia; CR1, first complete remission; CR2, second complete remission; CR, complete remission; t-MDS, therapy-related myelodysplastic syndrome; HLA, human leukocyte antigen; URD, unrelated donor; and CLL, chronic lymphocytic leukemia.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal